View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 24, 2011

Teva Brand-Name Drug Faces Generic Competition

Generic-drug manufacturing giant Teva Pharmaceutical is being dealt a taste of its own medicine, as its Copaxone multiple sclerosis treatment faces competition from a generic copy. Copazone generated more than $3bn of sales last year, and now Mylan and Momenta Pharmaceuticals have bo

By cms admin

Generic-drug manufacturing giant Teva Pharmaceutical is being dealt a taste of its own medicine, as its Copaxone multiple sclerosis treatment faces competition from a generic copy.

Copazone generated more than $3bn of sales last year, and now Mylan and Momenta Pharmaceuticals have both requested US Food and Drug Administration approval to sell copies ahead of patent expiries due to occur in 2014 and 2015.

Both companies are questioning the validity of the patents, a strategy used religiously by Teva, while the Israel-based generic company has launched cases against Mylan and Momenta citing patent infringement, a tactic used against Teva by Big Pharma.

Teva has also requested that the US Food and Drug Administration demand full-scale clinical trials of the generic versions, a request that has so far been denied.

In the US, Teva-produced generics account for almost one in five prescriptions.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology